Skip to main content
Top
Published in: International Journal of Hematology 2/2021

01-08-2021 | Disseminated Intravascular Coagulation | Original Article

Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats

Authors: Yukio Suga, Anna Kubo, Hideyuki Katsura, Yukiko Staub, Kiyomichi Tashiro, Shinya Yamada, Eriko Morishita, Hidesaku Asakura

Published in: International Journal of Hematology | Issue 2/2021

Login to get access

Abstract

Lipopolysaccharide (LPS) and tissue factor (TF) have frequently been used to induce disseminated intravascular coagulation (DIC) in experimental animal models. We have previously reported that the pathophysiology of DIC differs according to the inducing agents. However, inflammatory status and bleeding symptoms have not been fully compared between rat models of the two forms of DIC. We attempted to evaluate detailed characteristic features of LPS- and TF-induced DIC models, especially in regard to inflammatory status and bleeding symptoms, in addition to selected hemostatic parameters and pathologic findings in the kidneys. The degree of hemostatic activation in both types of experimental DIC was identical, based on the results of thrombin-antithrombin complex levels. Markedly elevated tumor necrosis factor, interleukin-6, and high-mobility group box-1 concentrations were observed with severe organ dysfunction and marked fibrin deposition in the kidney on administration of LPS, whereas markedly elevated d-dimer concentration and bleeding symptoms were observed with TF administration. Pathophysiology such as fibrinolytic activity, organ dysfunction, inflammation status, and bleeding symptom differed markedly between LPS- and TF-induced DIC models in rats. We, therefore, recommend that these disease models be assessed carefully as distinct entities to determine the implications of their experimental and clinical use.
Literature
1.
go back to reference Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–92.CrossRef Levi M, Ten Cate H. Disseminated intravascular coagulation. N Engl J Med. 1999;341:586–92.CrossRef
2.
go back to reference Seki Y, Wakaki K. Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy. Int J Hematol. 2016;104:506–11.CrossRef Seki Y, Wakaki K. Pathological findings in a case of bone marrow carcinosis due to gastric cancer complicated by disseminated intravascular coagulation and thrombotic microangiopathy. Int J Hematol. 2016;104:506–11.CrossRef
3.
go back to reference Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42.CrossRef Asakura H, Takahashi H, Uchiyama T, Eguchi Y, Okamoto K, Kawasugi K, et al. Proposal for new diagnostic criteria for DIC from the Japanese Society on Thrombosis and Hemostasis. Thromb J. 2016;14:42.CrossRef
4.
go back to reference Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113:34–44.CrossRef Ikezoe T. Advances in the diagnosis and treatment of disseminated intravascular coagulation in haematological malignancies. Int J Hematol. 2021;113:34–44.CrossRef
5.
go back to reference Asakura H. Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Int J Hematol. 2021;113:10–4.CrossRef Asakura H. Diversity of disseminated intravascular coagulation and selection of appropriate treatments. Int J Hematol. 2021;113:10–4.CrossRef
6.
go back to reference Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.CrossRef Asakura H. Classifying types of disseminated intravascular coagulation: clinical and animal models. J Intensive Care. 2014;2:20.CrossRef
7.
go back to reference Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128:1854–61.CrossRef Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016;128:1854–61.CrossRef
8.
go back to reference Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.CrossRef Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:840–51.CrossRef
9.
go back to reference Kimpara N, Tawara S, Kawasaki K. Thrombomodulin alfa prevents the decrease in platelet aggregation in rat models of disseminated intravascular coagulation. Thromb Res. 2019;179:73–80.CrossRef Kimpara N, Tawara S, Kawasaki K. Thrombomodulin alfa prevents the decrease in platelet aggregation in rat models of disseminated intravascular coagulation. Thromb Res. 2019;179:73–80.CrossRef
10.
go back to reference Wang B, Wu S, Ma Z, Wang T, Yang C. BMSCs pre-treatment ameliorates inflammation-related tissue destruction in LPS-induced rat DIC model. Cell Death Dis. 2018;9:1024.CrossRef Wang B, Wu S, Ma Z, Wang T, Yang C. BMSCs pre-treatment ameliorates inflammation-related tissue destruction in LPS-induced rat DIC model. Cell Death Dis. 2018;9:1024.CrossRef
11.
go back to reference Miyake Y, Yokota K, Fujishima Y, Sukamoto T. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat. Blood Coagul Fibrinolysis. 2001;12:349–57.CrossRef Miyake Y, Yokota K, Fujishima Y, Sukamoto T. The effects of danaparoid, dalteparin and heparin on tissue factor-induced experimental disseminated intravascular coagulation and bleeding time in the rat. Blood Coagul Fibrinolysis. 2001;12:349–57.CrossRef
12.
go back to reference Asakura H, Suga Y, Yoshida T, Ontachi Y, Mizutani T, Kato M, et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats. Blood Coagul Fibrinolysis. 2003;14:221–8.PubMed Asakura H, Suga Y, Yoshida T, Ontachi Y, Mizutani T, Kato M, et al. Pathophysiology of disseminated intravascular coagulation (DIC) progresses at a different rate in tissue factor-induced and lipopolysaccharide-induced DIC models in rats. Blood Coagul Fibrinolysis. 2003;14:221–8.PubMed
13.
go back to reference Brooks MB, Turk JR, Guerrero A, Narayanan PK, Nolan JP, Besteman EG, et al. Non-lethal endotoxin injection: a rat model of hypercoagulability. PLoS ONE. 2017;12:e0169976.CrossRef Brooks MB, Turk JR, Guerrero A, Narayanan PK, Nolan JP, Besteman EG, et al. Non-lethal endotoxin injection: a rat model of hypercoagulability. PLoS ONE. 2017;12:e0169976.CrossRef
14.
go back to reference Schochl H, Solomon C, Schulz A, Voelckel W, Hanke A, Van Griensven M, et al. Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17:266–72.CrossRef Schochl H, Solomon C, Schulz A, Voelckel W, Hanke A, Van Griensven M, et al. Thromboelastometry (TEM) findings in disseminated intravascular coagulation in a pig model of endotoxinemia. Mol Med. 2011;17:266–72.CrossRef
15.
go back to reference Popescu NI, Silasi R, Keshari RS, Girton A, Burgett T, Zeerleder SS, et al. Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways. Blood. 2018;132:849–60.CrossRef Popescu NI, Silasi R, Keshari RS, Girton A, Burgett T, Zeerleder SS, et al. Peptidoglycan induces disseminated intravascular coagulation in baboons through activation of both coagulation pathways. Blood. 2018;132:849–60.CrossRef
16.
go back to reference Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014;12:1010–9.CrossRef Iba T, Gando S, Thachil J. Anticoagulant therapy for sepsis-associated disseminated intravascular coagulation: the view from Japan. J Thromb Haemost. 2014;12:1010–9.CrossRef
17.
go back to reference Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44.CrossRef Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38–44.CrossRef
18.
go back to reference Schoergenhofer C, Schwameis M, Gelbenegger G, Buchtele N, Thaler B, Mussbacher M, et al. Inhibition of protease-activated receptor (PAR1) reduces activation of the endothelium, coagulation, fibrinolysis and inflammation during human endotoxemia. Thromb Haemost. 2018;118:1176–84.CrossRef Schoergenhofer C, Schwameis M, Gelbenegger G, Buchtele N, Thaler B, Mussbacher M, et al. Inhibition of protease-activated receptor (PAR1) reduces activation of the endothelium, coagulation, fibrinolysis and inflammation during human endotoxemia. Thromb Haemost. 2018;118:1176–84.CrossRef
19.
go back to reference Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101:2652–60.CrossRef Fiuza C, Bustin M, Talwar S, Tropea M, Gerstenberger E, Shelhamer JH, et al. Inflammation-promoting activity of HMGB1 on human microvascular endothelial cells. Blood. 2003;101:2652–60.CrossRef
20.
go back to reference Pachot A, Monneret G, Voirin N, Leissner P, Venet F, Bohe J, et al. Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin Immunol. 2005;114:61–9.CrossRef Pachot A, Monneret G, Voirin N, Leissner P, Venet F, Bohe J, et al. Longitudinal study of cytokine and immune transcription factor mRNA expression in septic shock. Clin Immunol. 2005;114:61–9.CrossRef
21.
22.
go back to reference Nakamura M, Takeuchi T, Kawahara T, Hirose J, Nakayama K, Hosaka Y, et al. Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models. Eur J Pharmacol. 2017;802:60–8.CrossRef Nakamura M, Takeuchi T, Kawahara T, Hirose J, Nakayama K, Hosaka Y, et al. Simultaneous targeting of CD14 and factor XIa by a fusion protein consisting of an anti-CD14 antibody and the modified second domain of bikunin improves survival in rabbit sepsis models. Eur J Pharmacol. 2017;802:60–8.CrossRef
23.
go back to reference Starr ME, Steele AM, Cohen DA, Saito H. Short-term dietary restriction rescues mice from lethal abdominal sepsis and endotoxemia and reduces the inflammatory/coagulant potential of adipose tissue. Crit Care Med. 2016;44:e509–19.CrossRef Starr ME, Steele AM, Cohen DA, Saito H. Short-term dietary restriction rescues mice from lethal abdominal sepsis and endotoxemia and reduces the inflammatory/coagulant potential of adipose tissue. Crit Care Med. 2016;44:e509–19.CrossRef
24.
go back to reference Kimura F, Takahashi A, Kitazawa J, Yoshino F, Katsura D, Amano T, et al. Successful conservative treatment for massive uterine bleeding with non-septic disseminated intravascular coagulation after termination of early pregnancy in a woman with huge adenomyosis: case report. BMC Womens Health. 2020;20:56.CrossRef Kimura F, Takahashi A, Kitazawa J, Yoshino F, Katsura D, Amano T, et al. Successful conservative treatment for massive uterine bleeding with non-septic disseminated intravascular coagulation after termination of early pregnancy in a woman with huge adenomyosis: case report. BMC Womens Health. 2020;20:56.CrossRef
25.
go back to reference Naymagon L, Mascarenhas J. Hemorrhage in acute promyelocytic leukemia: can it be predicted and prevented? Leuk Res. 2020;94:106356.CrossRef Naymagon L, Mascarenhas J. Hemorrhage in acute promyelocytic leukemia: can it be predicted and prevented? Leuk Res. 2020;94:106356.CrossRef
26.
go back to reference Ontachi Y, Asakura H, Takahashi Y, Hayashi T, Arahata M, Kadohira Y, et al. No interplay between the pathways mediating coagulation and inflammation in tissue factor-induced disseminated intravascular coagulation in rats. Crit Care Med. 2006;34:2646–50.CrossRef Ontachi Y, Asakura H, Takahashi Y, Hayashi T, Arahata M, Kadohira Y, et al. No interplay between the pathways mediating coagulation and inflammation in tissue factor-induced disseminated intravascular coagulation in rats. Crit Care Med. 2006;34:2646–50.CrossRef
27.
go back to reference Suga Y, Asakura H, Yoshida T, Omote M, Ontachi Y, Mizutani T, et al. Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats: a study examining the effect of an endothelin receptor antagonist. Blood Coagul Fibrinolysis. 2004;15:593–8.PubMed Suga Y, Asakura H, Yoshida T, Omote M, Ontachi Y, Mizutani T, et al. Relationship between endothelin and the pathophysiology of tissue factor-induced and lipopolysaccharide-induced disseminated intravascular coagulation in rats: a study examining the effect of an endothelin receptor antagonist. Blood Coagul Fibrinolysis. 2004;15:593–8.PubMed
28.
go back to reference Cezarette GN, Sartim MA, Sampaio SV. Inflammation and coagulation crosstalk induced by BJcuL, a galactose-binding lectin isolated from Bothrops jararacussu snake venom. Int J Biol Macromol. 2020;144:296–304.CrossRef Cezarette GN, Sartim MA, Sampaio SV. Inflammation and coagulation crosstalk induced by BJcuL, a galactose-binding lectin isolated from Bothrops jararacussu snake venom. Int J Biol Macromol. 2020;144:296–304.CrossRef
29.
go back to reference Fang X, Liao R, Yu Y, Li J, Guo Z, Zhu T. Thrombin induces secretion of multiple cytokines and expression of protease-activated receptors in mouse mast cell line. Mediat Inflamm. 2019;2019:4952131. Fang X, Liao R, Yu Y, Li J, Guo Z, Zhu T. Thrombin induces secretion of multiple cytokines and expression of protease-activated receptors in mouse mast cell line. Mediat Inflamm. 2019;2019:4952131.
30.
go back to reference Mhatre MV, Potter JA, Lockwood CJ, Krikun G, Abrahams VM. Thrombin augments LPS-induced human endometrial endothelial cell inflammation via PAR1 activation. Am J Reprod Immunol. 2016;76:29–37.CrossRef Mhatre MV, Potter JA, Lockwood CJ, Krikun G, Abrahams VM. Thrombin augments LPS-induced human endometrial endothelial cell inflammation via PAR1 activation. Am J Reprod Immunol. 2016;76:29–37.CrossRef
31.
go back to reference Schochl H, van Griensven M, Heitmeier S, Laux V, Kipman U, Roodt J, et al. Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 2017;21:51.CrossRef Schochl H, van Griensven M, Heitmeier S, Laux V, Kipman U, Roodt J, et al. Dual inhibition of thrombin and activated factor X attenuates disseminated intravascular coagulation and protects organ function in a baboon model of severe Gram-negative sepsis. Crit Care. 2017;21:51.CrossRef
32.
go back to reference Tang ZZ, Zhang YM, Zheng T, Huang TT, Ma TF, Liu YW. Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: in vivo and in vitro study. Phytomedicine. 2020;78:153314.CrossRef Tang ZZ, Zhang YM, Zheng T, Huang TT, Ma TF, Liu YW. Sarsasapogenin alleviates diabetic nephropathy through suppression of chronic inflammation by down-regulating PAR-1: in vivo and in vitro study. Phytomedicine. 2020;78:153314.CrossRef
33.
go back to reference Rahman A, True AL, Anwar KN, Ye RD, Voyno-Yasenetskaya TA, Malik AB. Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. Circ Res. 2002;91:398–405.CrossRef Rahman A, True AL, Anwar KN, Ye RD, Voyno-Yasenetskaya TA, Malik AB. Galpha(q) and Gbetagamma regulate PAR-1 signaling of thrombin-induced NF-kappaB activation and ICAM-1 transcription in endothelial cells. Circ Res. 2002;91:398–405.CrossRef
34.
go back to reference Noguchi D, Kuriyama N, Hibi T, Maeda K, Shinkai T, Gyoten K, et al. The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia/reperfusion injury in mice. Liver Transpl. 2021;27:363–84.CrossRef Noguchi D, Kuriyama N, Hibi T, Maeda K, Shinkai T, Gyoten K, et al. The impact of dabigatran treatment on sinusoidal protection against hepatic ischemia/reperfusion injury in mice. Liver Transpl. 2021;27:363–84.CrossRef
35.
go back to reference Yang H, Li T, Wei J, Zhang H, He S. Induction of tumor necrosis factor (TNF) release from subtypes of T cells by agonists of proteinase activated receptors. Mediat Inflamm. 2013;2013:165453. Yang H, Li T, Wei J, Zhang H, He S. Induction of tumor necrosis factor (TNF) release from subtypes of T cells by agonists of proteinase activated receptors. Mediat Inflamm. 2013;2013:165453.
36.
go back to reference DeLano FA, Hoyt DB, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in the intestine increases survival after experimental shock. Sci Transl Med. 2013;5:169ra11.CrossRef DeLano FA, Hoyt DB, Schmid-Schonbein GW. Pancreatic digestive enzyme blockade in the intestine increases survival after experimental shock. Sci Transl Med. 2013;5:169ra11.CrossRef
Metadata
Title
Detailed exploration of pathophysiology involving inflammatory status and bleeding symptoms between lipopolysaccharide- and tissue factor-induced disseminated intravascular coagulation in rats
Authors
Yukio Suga
Anna Kubo
Hideyuki Katsura
Yukiko Staub
Kiyomichi Tashiro
Shinya Yamada
Eriko Morishita
Hidesaku Asakura
Publication date
01-08-2021
Publisher
Springer Singapore
Published in
International Journal of Hematology / Issue 2/2021
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-021-03158-y

Other articles of this Issue 2/2021

International Journal of Hematology 2/2021 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine